Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Pembrolizumab and berahyaluronidase alfa-pmph |
| Trade Name | Keytruda Qlex |
| Synonyms | MK 3475A|MK3475A|MK-3475A |
| Drug Descriptions |
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) is a co-formulation of Keytruda (pembrolizumab) and berahyaluronidase alfa, which potentially enhances antitumor immune response (J Clin Oncol 2025 43: 16_suppl, TPS7090, NCI Drug Dictionary). Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) is FDA-approved for use in adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of Keytruda (Pembrolizumab) (FDA.gov). |
| DrugClasses | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| CAS Registry Number | NA |
| NCIT ID | C200181 |